Olympus Biotech Announces Reduced Sales Prices for New Hampshire Biopharmaceutical Manufacturing Facility
![](/46/pdcnewsitem/03/31/50/XRnlZxx150knCAr.png)
Olympus Biotech announced last week the initiation of an aggressive transaction process to find a buyer of its West Lebanon, NH manufacturing facility over the next 90 days. In recent months, the Company has received interest from buyers and contract manufacturing organisation (CMO) partners, but no deal has been consummated yet.
“We feel that this is an opportunity for a biotech or pharmaceutical company to acquire a world class site at a small fraction of the replacement cost. The value for the manufacturing plant and related assets has been reduced to a nominal value,” said Peter Gariepy, VP of Operations and Plant Manager. “We have written down the facility and are pursuing an aggressive sales process to showcase this attractive offer to the Life Sciences industry.”
The facility has an extensive history of manufacturing mammalian cell-based products for the biopharmaceutical industry and has a successful track record in producing both clinical and commercial bulk product. The facility is cGMP certified by several health authorities and has an excellent inspection record. Nearly 130 facility personnel have expertise in manufacturing and facility operations, engineering, development, quality assurance, quality control, validation, and operational excellence.
As an 180,000 sq ft manufacturing plant with expansion space and land for additional needs, the plant houses two mammalian cell culture suites with fixed and single use platforms as well as an area dedicated to process development activity. Each suite offers independent cell culture equipment trains and dedicated areas for product recovery and purification. Downstream areas can support an array of column chromatography and filtration processes including affinity, ion exchange, hydrophobic interaction, gel filtration, ultrafiltration, and diafiltration. Clinical aseptic fill capacity was recently introduced at the site using barrier isolator technology. Robust utility systems support 24/7 operations across all manufacturing and support functions.
To see a video tour of the facility please visit:
www.olympusbiotechcmo.com/index.php/gmp-contract-manufacturing/our-facility
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance